1995
DOI: 10.1055/s-2007-979766
|View full text |Cite
|
Sign up to set email alerts
|

Vigabatrin in Childhood Epilepsy: A 5-Year Follow-Up Study

Abstract: In an retrospective uncontrolled long-term study in 30 children with intractable epilepsy, it was found that treatment with vigabatrin resulted in a seizure reduction of more than 50% at 1-year follow-up in 40% of the children. The responders were all children with partial seizures. Side effects were mild and did not lead to discontinuation of the drug. Increased numbers of seizures were seen in three cases. A moderate weight increase was seen in 27% of the children. At 5-year follow-up 7 children (23%) still … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
13
0

Year Published

1997
1997
2022
2022

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(13 citation statements)
references
References 3 publications
0
13
0
Order By: Relevance
“…Vigabatrin (Sabril, Hoechst Marion Roussel/ Aventis Ltd) is an inhibitor of g-aminobutyric (GABA) transaminase and has been used as an effective second-line medication in the treatment of infantile seizures, 1 seizures associated with tuberous sclerosis, 2 and epilepsy of partial onset. 3 Its action is to potentiate the effect of GABAFan inhibitory neurotransmitterFby preventing its inactivation.…”
Section: Introductionmentioning
confidence: 99%
“…Vigabatrin (Sabril, Hoechst Marion Roussel/ Aventis Ltd) is an inhibitor of g-aminobutyric (GABA) transaminase and has been used as an effective second-line medication in the treatment of infantile seizures, 1 seizures associated with tuberous sclerosis, 2 and epilepsy of partial onset. 3 Its action is to potentiate the effect of GABAFan inhibitory neurotransmitterFby preventing its inactivation.…”
Section: Introductionmentioning
confidence: 99%
“…Vigabatrin (Sabril, Aventis Pharma, Laval, Canada) is an effective and popular γ-aminobutyric acid-ergic (GABA-ergic) anticonvulsant used in the management of infantile spasm (West syndrome), 1,2 in seizures associated with tuberous sclerosis, 3 and in partial seizures of adults as adjunctive therapy. 4 It acts by irreversible inhibition of GABA transaminase with the resultant accumulation of the inhibitory neurotransmitter GABA in the brain with even higher concentrations in the retina.…”
mentioning
confidence: 99%
“…[296,298,300,303,305,307,308,359,360] Weight gain is attributed to increased appetite in several studies. [300,303,308] Fatal hepatotoxicity was reported in a 3-yearold with a history of prematurity and perinatal cerebral haemorrhage treated with vigabatrin and phenobarbital for 9 months.…”
Section: Gastrointestinalmentioning
confidence: 99%